Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$120 Mln
Revenue (TTM)
$64 Mln
Net Profit (TTM)
$0 Mln
ROE
-2.6 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
24.6
Industry P/E
--
EV/EBITDA
-1
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-0.4
Face value
--
Shares outstanding
245,402,000
CFO
$-713.19 Mln
EBITDA
$-923.68 Mln
Net Profit
$-1,087.03 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Sangamo Therapeutics (SGMO)
| -51.0 | 11.1 | -49.0 | 0.0 | -47.5 | -46.1 | -26.5 |
|
BSE Sensex*
| 4.3 | -0.9 | 10.5 | 6.0 | 16.6 | 19.4 | 11.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Sangamo Therapeutics (SGMO)
| 87.9 | -82.8 | -58.1 | -51.9 | 86.4 | -27.1 | -29.9 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Sangamo Therapeutics (SGMO)
|
0.5 | 120.5 | 63.8 | -79.5 | -126.9 | -360.8 | -- | 24.6 |
| 51.6 | 7,919.9 | 1,208.8 | 131.7 | 13.4 | 6.3 | 60.9 | 3.9 | |
| 128.3 | 8,274.7 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.2 | |
| 151.0 | 7,460.2 | 4,022.6 | -31.6 | 3.7 | -1.1 | -- | 2.3 | |
| 53.3 | 10,095.9 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.2 | |
| 41.8 | 11,341.9 | 2,298.9 | 643.6 | 35.4 | 29.2 | 19 | 5.3 | |
| 301.0 | 8,572.2 | 2,156.6 | 416.4 | 21.2 | 56.5 | 22.8 | 14.4 | |
| 26.0 | 10,314.4 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 125.0 | 12,371.7 | 2,412.6 | 305.8 | 20.5 | 11.6 | 42.2 | 4.9 | |
| 288.6 | 12,781.0 | 2,994.1 | 1,210.7 | 51.4 | 18.8 | 11.3 | 1.9 |
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage... product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A. Its preclinical development products focus on tauopathies, ALS/FTD, and huntington's diseases Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California. Read more
CEO, President & Director
Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.
CEO, President & Director
Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.
Headquarters
Richmond, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Sangamo Therapeutics Inc (SGMO) stood at $ 136 Mln as on 31-Mar-25
The share price of Sangamo Therapeutics Inc (SGMO) is $0.50 (NASDAQ) as of 16-Jun-2025 16:18 EDT. Sangamo Therapeutics Inc (SGMO) has given a return of -47.47% in the last 3 years.
Sangamo Therapeutics Inc (SGMO) has a market capitalisation of $ 120 Mln as on 13-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Sangamo Therapeutics Inc (SGMO) is 24.56 times as on 13-Jun-2025, a 827% premium to its peers’ median range of 2.65 times.
Since, TTM earnings of Sangamo Therapeutics Inc (SGMO) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Sangamo Therapeutics Inc (SGMO) and enter the required number of quantities and click on buy to purchase the shares of Sangamo Therapeutics Inc (SGMO).
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A. Its preclinical development products focus on tauopathies, ALS/FTD, and huntington's diseases Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California.
The CEO & director of Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.. is Sangamo Therapeutics Inc (SGMO), and CFO & Sr. VP is Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D..
There is no promoter pledging in Sangamo Therapeutics Inc (SGMO).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,247
|
|
|
1,229
|
|
|
1,130
|
|
|
1,073
|
|
|
1,050
|
|
|
869
|
|
|
827
|
|
|
808
|
|
|
742
|
| Sangamo Therapeutics Inc. (SGMO) | Ratios |
|---|---|
|
Return on equity(%)
|
-360.8
|
|
Operating margin(%)
|
-126.89
|
|
Net Margin(%)
|
-124.61
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Sangamo Therapeutics Inc (SGMO) was $0 Mln.
$0.01
(
